NO931840L - Protein-C-derivater - Google Patents

Protein-C-derivater

Info

Publication number
NO931840L
NO931840L NO931840A NO931840A NO931840L NO 931840 L NO931840 L NO 931840L NO 931840 A NO931840 A NO 931840A NO 931840 A NO931840 A NO 931840A NO 931840 L NO931840 L NO 931840L
Authority
NO
Norway
Prior art keywords
derivatives
human protein
protein
producing
high activity
Prior art date
Application number
NO931840A
Other languages
English (en)
Other versions
NO311299B1 (no
NO931840D0 (no
Inventor
Bruce Edwaed Gerlitz
Brian William Grinnell
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO931840D0 publication Critical patent/NO931840D0/no
Publication of NO931840L publication Critical patent/NO931840L/no
Publication of NO311299B1 publication Critical patent/NO311299B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO19931840A 1992-05-21 1993-05-19 Protein C derivater, rekombinant DNA molekyl, kodende dette samt fremgangsmåte for fremstilling av proteinene NO311299B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88719192A 1992-05-21 1992-05-21

Publications (3)

Publication Number Publication Date
NO931840D0 NO931840D0 (no) 1993-05-19
NO931840L true NO931840L (no) 1993-11-22
NO311299B1 NO311299B1 (no) 2001-11-12

Family

ID=25390640

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19931840A NO311299B1 (no) 1992-05-21 1993-05-19 Protein C derivater, rekombinant DNA molekyl, kodende dette samt fremgangsmåte for fremstilling av proteinene

Country Status (23)

Country Link
US (1) US5453373A (no)
EP (1) EP0575054B1 (no)
JP (1) JP3564150B2 (no)
KR (1) KR100291529B1 (no)
CN (1) CN1080658A (no)
AT (1) ATE286121T1 (no)
AU (1) AU661901B2 (no)
BR (1) BR9301944A (no)
CA (1) CA2096604C (no)
CZ (1) CZ286016B6 (no)
DE (1) DE69333727T2 (no)
DK (1) DK0575054T3 (no)
ES (1) ES2233925T3 (no)
FI (1) FI932282A7 (no)
HU (1) HU218408B (no)
IL (1) IL105757A0 (no)
MX (1) MX9302917A (no)
MY (1) MY110664A (no)
NO (1) NO311299B1 (no)
NZ (1) NZ247651A (no)
PH (1) PH29911A (no)
PT (1) PT575054E (no)
RU (1) RU2122004C1 (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2067525C (en) * 1991-05-09 1998-09-15 Helmut G. Alt Organometallic fluorenyl compounds, preparation and use
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5716795A (en) * 1991-10-04 1998-02-10 Matschiner; John T. Thrombomodulin-based coagulometric assay of the protein C system
WO1993007491A1 (en) * 1991-10-04 1993-04-15 Board Of Regents Of The University Of Nebraska A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
UA55448C2 (uk) 1997-04-28 2003-04-15 Елі Ліллі Енд Компані Стійка ліофілізована лікарська форма з активованим білком с (варіанти) та виріб, який її містить
WO1998055142A1 (en) * 1997-06-05 1998-12-10 Eli Lilly And Company Methods for treating thrombotic disorders
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
CA2338766A1 (en) * 1998-07-31 2000-02-10 Eli Lilly And Company Cryogranulation of activated protein c
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
WO2000023101A1 (en) 1998-10-22 2000-04-27 Eli Lilly And Company Methods for treating sepsis
AU1477000A (en) 1998-11-13 2000-06-05 Eli Lilly And Company Method of treating heparin-induced thrombocytopenia
WO2000030677A1 (en) 1998-11-20 2000-06-02 Eli Lilly And Company Method of treating viral hemorrhagic fever
EP1133314B1 (en) 1998-11-23 2003-02-19 Eli Lilly And Company Protein c for the treatment of sickle cell disease and thalassemia
US6998122B1 (en) * 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
CA2391651A1 (en) * 1999-11-19 2001-05-25 Eli Lilly And Company Protein c derivatives
WO2001057193A2 (en) * 2000-02-02 2001-08-09 Eli Lilly And Company Protein c derivatives
CA2400187A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
JP4071105B2 (ja) * 2000-10-18 2008-04-02 マキシゲン・エイピーエス プロテインｃまたは活性化プロテインｃ様分子
BR0114771A (pt) * 2000-10-18 2004-07-27 Maxygen Aps Moléculas de proteìna c ou semelhantes a proteìna c ativada
US20040198652A1 (en) * 2001-04-24 2004-10-07 Carter J. Paul Methods and compositions for preventing and treating septic shock and endotoxemia
AU2003213146A1 (en) * 2002-03-08 2003-09-22 Eli Lilly And Company Activated protein c formulations
AU2003232176A1 (en) * 2002-06-14 2003-12-31 Maxygen Aps Protein c variants with altered properties
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
JP2008507561A (ja) * 2004-07-23 2008-03-13 ザ ユニバーシティ オブ ロチェスター 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
NZ561925A (en) * 2005-04-13 2010-04-30 Astrazeneca Ab A host cell comprising a vector for production of proteins requiring gamma-carboxylation
AU2006261555A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor lll polymorphisms associated with prediction of subject outcome and response to therapy
CA2654761A1 (en) * 2006-06-09 2007-12-13 The University Of British Columbia Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
US20100184672A1 (en) * 2007-06-18 2010-07-22 Mccarty Owen J T Protein c for use in maintaining hemostasis
US20110171200A1 (en) * 2008-01-15 2011-07-14 Walley Keith R Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
KR20110114587A (ko) 2008-12-19 2011-10-19 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 세린 프로테아제 유도체 및 혈액응고 장애의 치료 또는 예방의 용도
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
AU2013286812B2 (en) 2012-07-04 2017-04-20 Zz Biotech Llc Treatment of inflammatory skin disorders
PL3131572T3 (pl) 2014-04-16 2022-02-07 Zz Biotech Llc Analog apc do zastosowania w zaleczaniu rany
PT3137102T (pt) 2014-04-16 2021-09-28 Zz Biotech Llc Apc para utilização no tratamento de cicatrização cutânea anormal
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1637807A1 (ru) * 1984-04-10 1991-03-30 Полтавский медицинский стоматологический институт Средство дл индивидуальной профилактики венерических заболеваний у мужчин
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c

Also Published As

Publication number Publication date
RU2122004C1 (ru) 1998-11-20
FI932282L (fi) 1993-11-22
HUT69615A (en) 1995-09-28
DE69333727T2 (de) 2005-12-15
CZ286016B6 (cs) 1999-12-15
CA2096604C (en) 2003-12-16
JPH0680698A (ja) 1994-03-22
MX9302917A (es) 1993-11-01
EP0575054A3 (en) 1995-04-19
EP0575054A2 (en) 1993-12-22
FI932282A0 (fi) 1993-05-19
KR100291529B1 (ko) 2001-06-01
MY110664A (en) 1999-01-30
CN1080658A (zh) 1994-01-12
EP0575054B1 (en) 2004-12-29
KR930023370A (ko) 1993-12-18
DE69333727D1 (de) 2005-02-03
NO311299B1 (no) 2001-11-12
ATE286121T1 (de) 2005-01-15
CZ94893A3 (en) 1994-01-19
BR9301944A (pt) 1993-11-30
PH29911A (en) 1996-09-16
US5453373A (en) 1995-09-26
PT575054E (pt) 2005-03-31
DK0575054T3 (da) 2005-04-25
JP3564150B2 (ja) 2004-09-08
AU661901B2 (en) 1995-08-10
NZ247651A (en) 1995-03-28
HU218408B (hu) 2000-08-28
HU9301461D0 (en) 1993-09-28
NO931840D0 (no) 1993-05-19
FI932282A7 (fi) 1993-11-22
CA2096604A1 (en) 1993-11-22
ES2233925T3 (es) 2005-06-16
IL105757A0 (en) 1993-09-22
AU3869993A (en) 1993-11-25

Similar Documents

Publication Publication Date Title
FI932282A0 (fi) Protein C-derivat
NO900770L (no) Produksjon av glykoseoksidase i rekombinante systemer.
GR3033146T3 (en) Modified polypeptides with increased biological activity
DE3382837D1 (de) Herstellung von funktionellen, menschlichen Urokinaseproteinen
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
NO910719D0 (no) Vektorer og forbindelser for ekspresjon av glykosyleringsmutanter av humant protein c.
IL90334A0 (en) Genetic transformation of b.thuringiensis,vectors used therefor,host cells transformed by the vectors and use of said cells as insecticides
ES2058479T3 (es) Compuestos peptidicos.
ATE111477T1 (de) 2'-halomethyliden, 2'-ethenyliden und 2'-ethynyl- adenosinderivate.
ATE202570T1 (de) Gene, die für macif proteine kodieren, expressionsvektoren mit diesem genen, und transformantenzellen mit diesem proteinen
ES2099274T3 (es) Derivados de estreptolisina o.
TR26073A (tr) Bacillus thuringiensis jenleri,toksinleri ve insektisid olarak kullanimlari.
ATE59777T1 (de) Therapeutische zusammenstellungen auf basis von 3-alkoxyflavonen und derivate von 3-alkoxyflavonen.
DE3862073D1 (de) Tetramethyl-cis-diaza-bicyclo(4.2.0.)oktan-3,5-dion-derivate mit differentiationsinduzierender aktivitaet.
ITRM930343A0 (it) Proteine ricombinanti, vettori per l'espressione e loro usi.
FI950779A7 (fi) Homepromoottorit, jotka ovat aktiivisia glukoosin läsnäollessa

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN NOVEMBER 2002